{"id":14851,"date":"2024-11-25T13:16:26","date_gmt":"2024-11-25T05:16:26","guid":{"rendered":"https:\/\/flcube.com\/?p=14851"},"modified":"2024-11-25T13:16:28","modified_gmt":"2024-11-25T05:16:28","slug":"hanx-biopharmaceuticals-files-for-ipo-on-hong-kong-stock-exchange","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=14851","title":{"rendered":"Hanx Biopharmaceuticals Files for IPO on Hong Kong Stock Exchange"},"content":{"rendered":"\n

China-based Hanx Biopharmaceuticals (Wuhan) Co., Ltd. has made an initial public offering (IPO) filing to the Hong Kong Stock Exchange (HKSE), with the unit price and other details yet to be disclosed. This move marks a significant step for the company as it seeks to expand its reach and funding in the global market.<\/p>\n\n\n\n

Focus on Next-Generation Immunotherapies<\/strong>
Since its inception in 2016, Hanx Bio has been dedicated to the development of next-generation immunotherapies. The company leverages its expertise in structural biology, translational medicine, and clinical development to create innovative treatments for various diseases.<\/p>\n\n\n\n

Innovative Pipeline and Clinical Stage Candidates<\/strong>
Hanx Bio boasts an innovative pipeline that includes three clinical stage candidate drugs for oncology: HX009, HX301, and HX044. Additionally, the company has seven preclinical stage candidate drugs, which include antibody drug conjugates, bispecific antibodies, and monoclonal antibodies targeting the autoimmune and tumor markets. HX008, another drug in their portfolio, has been licensed to a biopharma focused on cancer therapy.<\/p>\n\n\n\n

Core Product HX009 and Other Candidates’ Clinical Progress<\/strong>
Core product HX009, a bifunctional fusion protein targeting PD-1 and SIRP\u03b1, is currently undergoing a China Phase Ib study in advanced melanoma and a China Phase I\/II study in recurrent or refractory (r\/r) EBV+ non-Hodgkin lymphoma. HX009 has already concluded Phase I trials in Australia and China.<\/p>\n\n\n\n

HX301, a multi-target kinase inhibitor targeting CSF1R, ARK5, FLT-3, and CDK4\/6, is in Phase I study in China, with plans for a Phase II study combined with temozolomide in glioblastoma. Lastly, HX044, a CD47\u2013SIRP\u03b1-targeted product, has initiated a Phase I\/IIa study in advanced solid tumors in Austria, with a clinical filing under review in China.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Hanx Biopharmaceuticals (Wuhan) Co., Ltd. has made an initial public offering (IPO) filing to…<\/p>\n","protected":false},"author":1,"featured_media":14853,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2333,72],"class_list":["post-14851","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-hanx-biopharmaceuticals","tag-ipo"],"yoast_head":"\nHanx Biopharmaceuticals Files for IPO on Hong Kong Stock Exchange - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Hanx Biopharmaceuticals (Wuhan) Co., Ltd. has made an initial public offering (IPO) filing to the Hong Kong Stock Exchange (HKSE), with the unit price and other details yet to be disclosed. This move marks a significant step for the company as it seeks to expand its reach and funding in the global market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=14851\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hanx Biopharmaceuticals Files for IPO on Hong Kong Stock Exchange\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=14851\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-25T05:16:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-25T05:16:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/8fd1cdeaddbab12884b5b0792399620d.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"748\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14851#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14851\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hanx Biopharmaceuticals Files for IPO on Hong Kong Stock Exchange\",\"datePublished\":\"2024-11-25T05:16:26+00:00\",\"dateModified\":\"2024-11-25T05:16:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14851\"},\"wordCount\":289,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14851#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/8fd1cdeaddbab12884b5b0792399620d.png\",\"keywords\":[\"Hanx Biopharmaceuticals\",\"IPO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14851#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14851\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=14851\",\"name\":\"Hanx Biopharmaceuticals Files for IPO on Hong Kong Stock Exchange - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14851#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14851#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/8fd1cdeaddbab12884b5b0792399620d.png\",\"datePublished\":\"2024-11-25T05:16:26+00:00\",\"dateModified\":\"2024-11-25T05:16:28+00:00\",\"description\":\"China-based Hanx Biopharmaceuticals (Wuhan) Co., Ltd. has made an initial public offering (IPO) filing to the Hong Kong Stock Exchange (HKSE), with the unit price and other details yet to be disclosed. This move marks a significant step for the company as it seeks to expand its reach and funding in the global market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14851#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14851\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14851#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/8fd1cdeaddbab12884b5b0792399620d.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/8fd1cdeaddbab12884b5b0792399620d.png\",\"width\":1080,\"height\":748,\"caption\":\"Hanx Biopharmaceuticals Files for IPO on Hong Kong Stock Exchange\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14851#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hanx Biopharmaceuticals Files for IPO on Hong Kong Stock Exchange\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hanx Biopharmaceuticals Files for IPO on Hong Kong Stock Exchange - Insight, China's Pharmaceutical Industry","description":"China-based Hanx Biopharmaceuticals (Wuhan) Co., Ltd. has made an initial public offering (IPO) filing to the Hong Kong Stock Exchange (HKSE), with the unit price and other details yet to be disclosed. This move marks a significant step for the company as it seeks to expand its reach and funding in the global market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=14851","og_locale":"en_US","og_type":"article","og_title":"Hanx Biopharmaceuticals Files for IPO on Hong Kong Stock Exchange","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=14851","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-11-25T05:16:26+00:00","article_modified_time":"2024-11-25T05:16:28+00:00","og_image":[{"width":1080,"height":748,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/8fd1cdeaddbab12884b5b0792399620d.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=14851#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=14851"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hanx Biopharmaceuticals Files for IPO on Hong Kong Stock Exchange","datePublished":"2024-11-25T05:16:26+00:00","dateModified":"2024-11-25T05:16:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=14851"},"wordCount":289,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=14851#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/8fd1cdeaddbab12884b5b0792399620d.png","keywords":["Hanx Biopharmaceuticals","IPO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=14851#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=14851","url":"https:\/\/flcube.com\/?p=14851","name":"Hanx Biopharmaceuticals Files for IPO on Hong Kong Stock Exchange - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=14851#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=14851#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/8fd1cdeaddbab12884b5b0792399620d.png","datePublished":"2024-11-25T05:16:26+00:00","dateModified":"2024-11-25T05:16:28+00:00","description":"China-based Hanx Biopharmaceuticals (Wuhan) Co., Ltd. has made an initial public offering (IPO) filing to the Hong Kong Stock Exchange (HKSE), with the unit price and other details yet to be disclosed. This move marks a significant step for the company as it seeks to expand its reach and funding in the global market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=14851#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=14851"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=14851#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/8fd1cdeaddbab12884b5b0792399620d.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/8fd1cdeaddbab12884b5b0792399620d.png","width":1080,"height":748,"caption":"Hanx Biopharmaceuticals Files for IPO on Hong Kong Stock Exchange"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=14851#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hanx Biopharmaceuticals Files for IPO on Hong Kong Stock Exchange"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/8fd1cdeaddbab12884b5b0792399620d.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14851","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14851"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14851\/revisions"}],"predecessor-version":[{"id":14854,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14851\/revisions\/14854"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/14853"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14851"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14851"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14851"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}